<\/p>\n
UPDATE (February 2026):<\/em> Galderma announced that the U.S. Food and Drug Administration has accepted the Biologics License Application resubmission for RelabotulinumtoxinA, a key regulatory step toward potential U.S. approval.<\/p>\n \u201cWe pioneered the development of RelabotulinumtoxinA to address the growing demand for faster-acting and longer-lasting anti-wrinkle solutions,\u201d said Dr. Baldo Scassellati Sforzolini, Galderma\u2019s Global Head of R&D,\u00a0in a press release. \u201cWe\u2019re excited about the potential to bring this innovative neuromodulator to the U.S.\u201d<\/p>\n At the IMCAS 2025 conference in Paris, Galderma presented new data on its yet-to-be-released injectable, RelabotulinumtoxinA, or Relfydess, which is generating buzz for its potential to work faster and last longer than existing wrinkle relaxers. According to the company, some patients in a\u00a0phase IIIb trial\u2014an advanced study conducted before regulatory approval\u2014saw visible results as early as\u00a0Day 1\u00a0after treatment. That could set it apart from current neurotoxin treatments, which typically take\u00a0three to seven days\u00a0to show effects, depending on the product.<\/p>\n Beyond its rapid onset, the study also found that Relfydess maintained results for\u00a0up to six months, with the median time to return to baseline severity for frown lines and crow\u2019s-feet reported between\u00a024 and 27 weeks. In comparison, most currently available neurotoxins last around three to four months before a touch-up is needed.<\/p>\n What sets it apart, according to Galderma, is its formulation. Unlike traditional botulinum toxin treatments, which come in a\u00a0powder form that must be mixed with saline before injection, Relfydess is a\u00a0ready-to-use liquid. This innovation, developed with Galderma\u2019s\u00a0PEARL Technology, is designed to preserve the integrity of the active ingredient, minimize inconsistencies in dosing and streamline the injection process for practitioners.<\/p>\n \u201cWe are proud to share our latest RelabotulinumtoxinA data, which reaffirms the sustained clinical effect and patient satisfaction observed in our READY clinical trial program,\u201d said Dr. Baldo Scassellati Sforzolini in a previous press release. \u201cThese findings, together with our proprietary PEARL Technology, reinforce RelabotulinumtoxinA as a safe, effective and innovative treatment option and uphold Galderma\u2019s position at the forefront of aesthetic advancements.\u201d<\/p>\n Relfydess is not yet FDA-approved, but Galderma confirmed that the FDA has accepted its Biologics License Application resubmission for the treatment of moderate-to-severe glabellar lines and lateral canthal lines in adults. The company has not announced a U.S. launch timeline.<\/p>\n The neurotoxin has already been approved in more than 20 markets globally, including the European Union and the United Kingdom, and continues to be reviewed by regulatory authorities worldwide. With increasing demand for faster, longer-lasting wrinkle relaxers, it remains one to watch.<\/p>\n<\/p><\/div>\nHow long does Relfydess last?<\/h2>\n
How It\u2019s Different<\/h2>\n
What Galderma Says<\/h2>\n
When will Relfydess be available?<\/h2>\n